Systemic considerations in the management of diabetic retinopathy

American Journal of Ophthalmology

Volumn 132, Issue 5, 2001, Pages 760-776

  Aiello, Lloyd Paul ^a,b   Cahill, Mark T ^a   Wong, Jun S ^a  

^a JOSLIN DIABETES CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRINOLYTIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; SORBINIL; TRIACYLGLYCEROL;

ANTICOAGULATION; BLOOD CLOT LYSIS; DIABETIC RETINOPATHY; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY DISEASE; LASER COAGULATION; LIPID BLOOD LEVEL; PATIENT CARE; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; RETINA BLOOD FLOW; REVIEW; RISK FACTOR; SMOKING; VITREOUS HEMORRHAGE;

EID: 0034754723     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(01)01124-2     Document Type: Article

References (34)

1. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984;91:1464-74.
2. The Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 1976;81:383-96.
3. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology 1981;88:583-600.
4. The Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806.
5. Kahn HA, Hiller R. Blindness caused by diabetic retinopathy. Am J Ophthalmol 1974;78:58-67.
6. Palmberg PF. Diabetic Retinopathy. Diabetes 1977;26:703-9.
7. The Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991;98:766-85.
8. The Early Treatment Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Arch Ophthalmol 1995;113:1144-55.
9. Aiello LP, Gardner TW, King GL, et al. Diabetic retinopathy: Technical review. Diabetes Care 1998;21:143-56.
10. The Early Treatment Diabetic Retinopathy Study Research Group. Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report no. 3. Int Ophthalmol Clin 1987;27:254-64.
11. The Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report no. 4. Int Ophthalmol Clin 1987;27:265-72.
12. The Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991;98:766-85.
13. American Diabetes Association. Diabetic Retinopathy: Position Statement. Diabetes Care 1998;21:157-9.
14. National Diabetes Data Group. Diabetes in America., 2 ed. Vol. NIH publ. no. 95-1468. Washington: US Govt. Printing Office, 1995.
15. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. VI. Retinal photocoagulation. Ophthalmology 1987;94:747-53.
16. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long- term incidence of macular edema. Ophthalmology 1995;102:7-16.
17. Javitt JC, Canner JK, Sommer A. Cost effectiveness of current approaches to the control of retinopathy in type 1 diabetics. Ophthalmology 1989;96:255-64.
18. Javitt JC, Aiello LP, Chiang Y, et al. Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform. Diabetes Care 1994;17:909-17.
19. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. [see comments]. N Engl J Med 1993;329:977-86.
20. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology 1995;102:647-61.
21. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group [published erratum appears in N Engl J Med 2000 May 4;342(18):1376]. N Engl J Med 2000;342:381-9.
22. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial [published erratum appears in Arch Ophthalmol Nov;116(11):1469]. Arch Ophthalmol 1998;116:874-86.
23. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [see comments]. Lancet 1998;352:837-53.
24. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. UK Prospective Diabetes Study Group [see comments] [published erratum appears in BMJ 1999 Jan 2;318(7175): 29]. BMJ 1998;317:703-13.
25. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 39. UK Prospective Diabetes Study Group [see comments]. BMJ 1998;317:713-20.
26. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(Suppl 2):B21-B29.
27. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [see comments]. Lancet 1998;352:837-53.
28. Prior MJ, Prout T, Miller D, et al. C-peptide and the classification of diabetes mellitus patients in the Early Treatment Diabetic Retinopathy Study. Report number 6. The ETDRS Research Group. Ann Epidemiol 1993;3:9-17.
29. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-36.
30. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984;102:527-32.
31. Ferris F. Early photocoagulation in patients with either type 1 or type 2 diabetes. Trans Am Ophthalmol Soc 1996;94:505-37.
32. Diabetic Retinopathy Vitrectomy Study Group. Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) report #1. Ophthalmology 1985;92:492-502.
33. The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5 [published erratum appears in Arch Ophthalmol 1990 Oct; 108(10):1452]. Arch Ophthalmol 1990;108:958-64.
34. Klein R, Klein BE, Lee KE, et al. The incidence of hypertension in insulin-dependent diabetes. Arch Intern Med 1996;156:622-7.